Formycon (FYB) Stock Overview
A biotechnology company, develops biosimilar drugs in Germany and Switzerland. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
FYB Community Fair Values
Create NarrativeSee what 19 others think this stock is worth. Follow their fair value or set your own to get alerts.
Formycon AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €23.15 |
| 52 Week High | €64.40 |
| 52 Week Low | €19.18 |
| Beta | 0.59 |
| 1 Month Change | -8.86% |
| 3 Month Change | -15.51% |
| 1 Year Change | -55.31% |
| 3 Year Change | -68.50% |
| 5 Year Change | -13.94% |
| Change since IPO | 160.11% |
Recent News & Updates
Recent updates
Expected Launches Of Stelara And Keytruda Biosimilars Will Strengthen Future Pipeline
The launch of biosimilars and strategic focus on high-growth areas indicate strong future revenue and earnings potential for Formycon.A Look At The Fair Value Of Formycon AG (ETR:FYB)
Jul 20
Formycon AG's (ETR:FYB) Prospects Need A Boost To Lift Shares
May 29We Believe Formycon's (ETR:FYB) Earnings Are A Poor Guide For Its Profitability
May 03Some Confidence Is Lacking In Formycon AG's (ETR:FYB) P/S
Jan 19We Think Formycon (ETR:FYB) Needs To Drive Business Growth Carefully
Dec 23Formycon AG's (ETR:FYB) Share Price Not Quite Adding Up
Sep 26We Think You Should Be Aware Of Some Concerning Factors In Formycon's (ETR:FYB) Earnings
Nov 05We're Hopeful That Formycon (ETR:FYB) Will Use Its Cash Wisely
Sep 04Analysts Just Published A Bright New Outlook For Formycon AG's (ETR:FYB)
Jul 13Bearish: Analysts Just Cut Their Formycon AG (ETR:FYB) Revenue and EPS estimates
Jun 02Here's Why We're Not Too Worried About Formycon's (ETR:FYB) Cash Burn Situation
May 23Here's Why We're Not At All Concerned With Formycon's (ETR:FYB) Cash Burn Situation
Feb 01We Think Formycon (ETR:FYB) Can Easily Afford To Drive Business Growth
Sep 25We're Interested To See How Formycon (ETR:FYB) Uses Its Cash Hoard To Grow
May 19Shareholder Returns
| FYB | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -5.9% | -0.4% | -1.8% |
| 1Y | -55.3% | -29.3% | 14.9% |
Return vs Industry: FYB underperformed the German Biotechs industry which returned -29.3% over the past year.
Return vs Market: FYB underperformed the German Market which returned 14.9% over the past year.
Price Volatility
| FYB volatility | |
|---|---|
| FYB Average Weekly Movement | 6.4% |
| Biotechs Industry Average Movement | 11.7% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in DE Market | 11.6% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: FYB has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: FYB's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 245 | Stefan Glombitza | www.formycon.com |
Formycon AG, a biotechnology company, develops biosimilar drugs in Germany and Switzerland. It provides ranibizumab and aflibercept used in the treatment of neovascular age-related macular degeneration, diabetic macular edema, choroidal neovascularization, proliferative diabetic retinopathy, and macular edema under the Ranivisio, Ongavia, Cimerli, Ranopto, Uptera, and Ravegza brand names, as well as AHZANTIVE, Baiama, and Fovlya brand names. The company’s pipeline includes ustekinumab used in the treatment of Crohn’s disease, ulcerative colitis, Plaque Psoriasis, and Psoriatic Arthritis under the Otulf, Fymskina, and Sitovab brand names.
Formycon AG Fundamentals Summary
| FYB fundamental statistics | |
|---|---|
| Market cap | €409.81m |
| Earnings (TTM) | -€169.77m |
| Revenue (TTM) | €51.78m |
Is FYB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FYB income statement (TTM) | |
|---|---|
| Revenue | €51.78m |
| Cost of Revenue | €52.29m |
| Gross Profit | -€514.00k |
| Other Expenses | €169.26m |
| Earnings | -€169.77m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
Nov 13, 2025
| Earnings per share (EPS) | -9.61 |
| Gross Margin | -0.99% |
| Net Profit Margin | -327.88% |
| Debt/Equity Ratio | 0% |
How did FYB perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/09/04 18:08 |
| End of Day Share Price | 2025/09/04 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Formycon AG is covered by 15 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Gerhard Orgonas | Berenberg |
| Benjamin Thielmann | Berenberg |
| Simon Scholes | First Berlin Equity Research GmbH |